Epilepsy is one of the most prevalent, serious neurological conditions, with approximately 600,000 people in the UK living with epilepsy, costing the National Health Service (NHS) an estimated £2 billion annually [1,2]. Yet, despite this, there are stark inequalities in research funding for epilepsy in comparison to other neurological conditions. In 2018, epilepsy received just 0.3% of the £4.8 billion funding spent on health-related research by the UK government [3]. Epilepsy is a compelling area for enhanced research support because there are preventable causes, and treatment paradigms that are ultra-precise (precision medicine strategies) and those that are agnostic to aetiology (such as neuromodulation) [4].
15
DIC
DIC
0